Transformed Follicular Lymphoma (tFL)
Oncology
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| kte-c19 | Kite Pharma, Inc. (KITE) |
Frequently asked questions
How many drugs are in development for Transformed Follicular Lymphoma (tFL)?
BioSniper tracks 1 drug in development for Transformed Follicular Lymphoma (tFL) across 1 company.
How many clinical trials target Transformed Follicular Lymphoma (tFL)?
There are 1 clinical trial targeting Transformed Follicular Lymphoma (tFL) tracked by BioSniper.
What is the prevalence of Transformed Follicular Lymphoma (tFL)?
The estimated prevalence of Transformed Follicular Lymphoma (tFL) is approximately 56.0 per 100,000 population.
Deep-dive into Transformed Follicular Lymphoma (tFL)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis